NCT04200755View on ClinicalTrials.gov

Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Localized Scleroderma
Interventions
DRUG

Dupilumab 300Mg Solution for Injection

First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)

OTHER

Placebo

First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance

Trial Locations (4)

10117

Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie, Berlin

46045

Helios St. Elisabeth Klinik Oberhausen, Klinik für Dermatologie, Venerologie und Allergologie, Oberhausen

50924

Uniklinik Köln, Klinik für Dermatologie und Venerologie, Cologne

72076

Universitäts-Hautklinik Tübingen, Tübingen

All Listed Sponsors
lead

University of Cologne

OTHER

NCT04200755 - Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma | Biotech Hunter | Biotech Hunter